CAS No.: 1034190-08-3
Molecular Formula: C8H18N2O4S
Formula Weight: 238.3
On September 13, 2023, Alzheon revealed that patients with early-stage AD who carried the apolipoprotein 4 allele (APOE4) and were given the experimental medication Valiltramiprosate for 24 months demonstrated a significant decline in plasma biomarkers of neurodegeneration, preservation of brain volume, and a beneficial effect on cognitive function.
˜ The safety profile of Valiltramiprosate was similar with prior evidence in more than 2,800 individuals with AD, and there was no elevated risk of vasogenic cerebral edema.
At Phase 3 therapeutic levels, valiltramiprosate has been demonstrated to totally prevent the synthesis of neurotoxic soluble beta-amyloid oligomers. Through a new method of action of the envelope molecule, valiltramiprosate entirely prevents the production of neurotoxic soluble amyloid oligomers in the human brain linked to the beginning and progression of cognitive symptoms of Alzheimer's disease. The FDA granted Fast Track status to the commercial synthetic medicine in 2017.
APOLLOE4 Phase 3 Trial
Efficacy and Safety Study of Valiltramiprosate in Patients with Early Alzheimer's Disease on the Public Synthesis Drug APOE4/4:Designed to evaluate the efficacy, safety of 265 mg of twice-daily oral Valiltramiprosate in patients with early stage AD who have two copies of the apolipoprotein ε4 allele (APOE4/4 purists), biomarkers, and imaging outcomes in patients who represent approximately 15% of patients with Alzheimer's disease. This is a 78-week, double-blind, randomized trial comparing oral Valiltramiprosate to placebo treatment.
